NCT04788966 is a clinical trial of the translation tool BabelDr in Diagnoses Disease, sponsored by University Hospital, Geneva.

Who is sponsoring NCT04788966?

NCT04788966 is sponsored by University Hospital, Geneva.

What drugs are being tested in NCT04788966?

Interventions in NCT04788966: the translation tool BabelDr.

What condition does NCT04788966 study?

NCT04788966 studies Diagnoses Disease.

Is NCT04788966 still recruiting?

NCT04788966 is currently completed. Last updated 9 March 2021.

Last reviewed 2021-03-09 · How we verify

NCT04788966

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of an Innovative Speech-enabled Translator in Emergency Settings

Completed Last updated 9 March 2021

What this trial tests

trial testing the translation tool BabelDr in Diagnoses Disease in 42 participants. Completed in 20 January 2020.

Timeline

29 November 2018

Primary endpoint
20 January 2020

20 January 2020

Quick facts

Lead sponsor	University Hospital, Geneva
Status	Completed
Study type	OBSERVATIONAL
Enrollment	42
Start date	29 November 2018
Primary completion	20 January 2020
Estimated completion	20 January 2020
Sites	1 location across Switzerland

Drugs / interventions tested

the translation tool BabelDr

Conditions studied

Diagnoses Disease — all drugs for Diagnoses Disease →

Sponsor

University Hospital, Geneva

Who can join

Eligibility, any sex, with Diagnoses Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Survey-based satisfaction, performance and technical features evaluation of a speech-enabled fixed-phrase translation tool (BabelDR) in an emergency department.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diagnoses Disease

Currently open trials in the same condition.

NCT06439901 — Optimizing Bronchopulmonary Cancer Screening · NA · recruiting
NCT04536220 — Establish Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer · recruiting
NCT04567368 — TB-CAPT MTB/XDR Study · active not recruiting
NCT06616506 — Artificial Intelligence for Highly Myopic Cataract · recruiting

Other University Hospital, Geneva trials

Trials by the same sponsor.

NCT07506356 — Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors · recruiting
NCT07267624 — EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study) · NA · not yet recruiting
NCT06710210 — Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventi · NA · not yet recruiting
NCT07173348 — Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea · NA · not yet recruiting
NCT07129655 — Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Ch · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04788966 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Geneva
Last refreshed: 9 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04788966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing